MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
TransMedics Group Operating Income 2011-2025 | TMDX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income TransMedics Group
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.5 M | -28.7 M | -31.4 M | -39.4 M | -26.4 M | -29.6 M | -20.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.5 M | -39.4 M | -19.8 M |
Quarterly Operating Income TransMedics Group
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.6 M | 27.4 M | - | 3.92 M | 12.5 M | 12.4 M | - | -28.3 M | -906 K | -2.09 M | - | -5.54 M | -9.74 M | -9.37 M | - | -11.7 M | -9.87 M | -6.51 M | -5.9 M | -4.61 M | -7.86 M | -8.02 M | -8.69 M | -7.24 M | -7.7 M | -5.96 M | -6.36 M | -3.94 M | -5.16 M | -4.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.6 M | -28.3 M | -2.59 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 96.13 | 0.04 % | $ 141 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.6 | - | $ 125 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 301.75 | 0.24 % | $ 8.51 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 48.12 | 0.21 % | $ 7.17 K | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 124.81 | 0.22 % | $ 217 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 2.97 | 4.58 % | $ 111 M |  France |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.14 | 3.64 % | $ 18.4 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 97.06 | 0.48 % | $ 1.23 B | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
129 M | $ 63.08 | -0.27 % | $ 3.42 B |  Britain |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M |  Israel |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.54 | - | $ 685 M | Israel |
 |
InMode Ltd.
INMD
|
113 M | $ 14.47 | 0.7 % | $ 1.15 B | Israel |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 157.84 | 0.69 % | $ 11.8 B | USA |
 |
Myomo
MYO
|
-10.7 M | $ 1.02 | 12.09 % | $ 7.19 M | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.86 | 0.43 % | $ 88.4 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 14.49 | 0.84 % | $ 392 M | USA |
|
LENSAR
LNSR
|
-10.7 M | $ 12.01 | -0.08 % | $ 138 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 14.53 | 0.07 % | $ 95.2 M | USA |
 |
AxoGen
AXGN
|
-3.29 M | $ 32.64 | -0.61 % | $ 1.44 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 40.17 | 1.34 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 17.41 | 0.75 % | $ 402 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 88.43 | -0.38 % | $ 12 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 12.66 | 0.56 % | $ 975 M | USA |